Plasma Amyloid-β as a Biomarker in Alzheimer's Disease: The AIBL Study of Aging
| Autor: | Colin L. Masters, Veer Bala Gupta, James Lui, Ralph N. Martins, Mark Rodrigues, Kevin Taddei, Jasmin Dromey, Karl De Ruyck, Belinda M. Brown, Kelly K. Pertile, Jonathan K. Foster, Christopher Fowler, Qiao-Xin Li, Rebecca L. Rumble, Katrina M. Laughton, Simon M. Laws, Kathryn A. Ellis, Christopher C. Rowe, Alan Rembach, Noel G. Faux, Ashley I. Bush, Mira Rimajova, David Ames, Peter J. Hudson, Victor L. Villemagne, Cassandra Szoeke, Vanessa Ward, Tania Taddei, Brett Trounson |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Male
Oncology Aging medicine.medical_specialty Pathology Amyloid beta Enzyme-Linked Immunosorbent Assay Disease Neuropsychological Tests Risk Assessment Cohort Studies Pathogenesis chemistry.chemical_compound Apolipoproteins E Alzheimer Disease Internal medicine mental disorders medicine Humans Dementia Multiplex Life Style Aged Amyloid beta-Peptides biology business.industry General Neuroscience Australia Brain General Medicine medicine.disease Psychiatry and Mental health Clinical Psychology Cross-Sectional Studies Socioeconomic Factors chemistry biology.protein Biomarker (medicine) Female Geriatrics and Gerontology Alzheimer's disease Pittsburgh compound B business Biomarkers |
| Zdroj: | Journal of Alzheimer's Disease. 20:1233-1242 |
| ISSN: | 1875-8908 1387-2877 |
| Popis: | Amyloid-beta (Abeta) plays a central role in the pathogenesis of Alzheimer's disease (AD) and has been postulated as a potential biomarker for AD. However, there is a lack of consensus as to its suitability as an AD biomarker. The objective of this study was to determine the significance of plasma Abeta as an AD biomarker and its relationship with Abeta load and to determine the effect of different assay methods on the interpretation of Abeta levels. Plasma Abeta1-40, Abeta1-42, and N-terminal cleaved fragments were measured using both a commercial multiplex assay and a well-documented ELISA in 1032 individuals drawn from the well-characterized Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Further, Abeta levels were compared to Abeta load derived from positron-emission tomography (PET) with the Pittsburgh compound B (PiB). Lower Abeta1-42 and Abeta1-42/1-40 ratio were observed in patients with AD and inversely correlated with PiB-PET derived Abeta load. However, assay methodology significantly impacted the interpretation of data. The cross-sectional analysis of plasma Abeta isoforms suggests that they may not be sufficient per se to diagnose AD. The value of their measurement in prognosis and monitoring of AD interventions needs further study, in addition to future longitudinal comparisons together with other predictors, which will determine whether plasma Abeta has diagnostic value in a panel of biomarkers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|